---
document_datetime: 2023-09-21 21:32:27
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/qdenga-epar-all-authorised-presentations_en.pdf
document_name: qdenga-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.0747349
conversion_datetime: 2025-12-27 16:03:19.820481
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Content (concentration) Pack size

| EU/1/22/1699/001   | Qdenga   | --¹   | Powder and solvent for solution for injection   | Subcutaneous use   | powder: vial (glass); solvent: vial (glass)               | 0.5 ml   | 1 vial + 1 vial                               |
|--------------------|----------|-------|-------------------------------------------------|--------------------|-----------------------------------------------------------|----------|-----------------------------------------------|
| EU/1/22/1699/002   | Qdenga   | --¹   | Powder and solvent for solution for injection   | Subcutaneous use   | powder: vial (glass); solvent: vial (glass)               | 0.5 ml   | 10 vials + 10 vials                           |
| EU/1/22/1699/003   | Qdenga   | --¹   | Powder and solvent for solution for injection   | Subcutaneous use   | powder: vial (glass); solvent: pre-filled syringe (glass) | 0.5 ml   | 1 vial + 1 pre-filled syringe                 |
| EU/1/22/1699/004   | Qdenga   | --¹   | Powder and solvent for solution for injection   | Subcutaneous use   | powder: vial (glass); solvent: pre-filled syringe (glass) | 0.5 ml   | 5 vials + 5 pre- filled syringes              |
| EU/1/22/1699/005   | Qdenga   | --¹   | Powder and solvent for solution for injection   | Subcutaneous use   | powder: vial (glass); solvent: pre-filled syringe (glass) | 0.5 ml   | 1 vial + 1 pre-filled syringe + 2 needles     |
| EU/1/22/1699/006   | Qdenga   | --¹   | Powder and solvent for solution for injection   | Subcutaneous use   | powder: vial (glass); solvent: pre-filled syringe (glass) | 0.5 ml   | 5 vials + 5 pre- filled syringes + 10 needles |

- --¹

After reconstitution, 1 dose (0.5 mL) contains: Dengue virus serotype 1 (live, attenuated)*: ≥ 3.3 log10 PFU**/dose Dengue virus serotype 2 (live, attenuated)#: ≥ 2.7 log10 PFU**/dose Dengue virus serotype 3 (live, attenuated)*: ≥ 4.0 log10 PFU**/dose Dengue virus serotype 4 (live, attenuated)*: ≥ 4.5 log10 PFU**/dose *Produced in Vero cells by recombinant DNA technology. Genes of serotype-specific surface proteins engineered into dengue type 2 backbone #Produced in Vero cells by recombinant DNA technology **PFU = Plaque-forming units